Fifty-one (51) patients had IDH1/2-mutant tumors that were transformed from WHO Grade III anaplastic astrocytoma or low-grade gliomas, or diagnosed as IDH-mutant GBM by 2016 WHO criteria. This evidence concerns the gene IDH1 and central nervous system cancer.